(Q34593013)

English

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

Borrelia burgdorferi

0 references

Peter Gottfried Kremsner

14

object named as

Peter G Kremsner

1 reference

Europe PubMed Central

3 August 2017

2

object named as

P Noel Barrett

1 reference

Europe PubMed Central

3 August 2017

author name string

Nina Wressnigg

1

1 reference

Europe PubMed Central

3 August 2017

Eva-Maria Pöllabauer

3

1 reference

Europe PubMed Central

3 August 2017

Maria O'Rourke

4

1 reference

Europe PubMed Central

3 August 2017

Daniel Portsmouth

5

1 reference

Europe PubMed Central

3 August 2017

Michael G Schwendinger

6

1 reference

Europe PubMed Central

3 August 2017

Brian A Crowe

7

1 reference

Europe PubMed Central

3 August 2017

Ian Livey

8

1 reference

Europe PubMed Central

3 August 2017

Thomas Dvorak

9

1 reference

Europe PubMed Central

3 August 2017

Bernhard Schmitt

10

1 reference

Europe PubMed Central

3 August 2017

Markus Zeitlinger

11

1 reference

Europe PubMed Central

3 August 2017

Herwig Kollaritsch

12

1 reference

Europe PubMed Central

3 August 2017

Meral Esen

13

1 reference

Europe PubMed Central

3 August 2017

Tomas Jelinek

15

1 reference

Europe PubMed Central

3 August 2017

Roland Aschoff

16

1 reference

Europe PubMed Central

3 August 2017

Roland Weisser

17

1 reference

Europe PubMed Central

3 August 2017

Ingomar F K Naudts

18

1 reference

Europe PubMed Central

3 August 2017

Gerald Aichinger

19

1 reference

Europe PubMed Central

3 August 2017

publication date

3 September 2014

1 reference

Europe PubMed Central

3 August 2017

Clinical and Vaccine Immunology

1 reference

Europe PubMed Central

3 August 2017

21

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

1490-1499

1 reference

Europe PubMed Central

3 August 2017

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Notice to readers: final 2012 reports of nationally notifiable infectious diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Differentiation of reinfection from relapse in recurrent Lyme disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Molecular programming of B cell memory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Lyme borreliosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Vaccines against Lyme disease: What happened and what lessons can we learn?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Plasma cells negatively regulate the follicular helper T cell program

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Reinfection in patients with Lyme disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Asymptomatic Infection with Borrelia burgdorferi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Incidence and cumulative frequency of endemic Lyme disease in a community

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

7 July 2018

Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

27 October 2018

Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

27 October 2018

Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

27 October 2018

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4248771

27 October 2018

Longitudinal study of Lyme borreliosis in a high risk population in Switzerland

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new approach to a Lyme disease vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CDC estimates 300,000 US cases of Lyme disease annually

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activity of Borrelia burgdorferi antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serologic diagnosis of Lyme disease using recombinant outer surface proteins A and B and flagellin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/CVI.00406-14

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34593013&oldid=1424707578"